<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="366105">
  <stage>Registered</stage>
  <submitdate>1/05/2014</submitdate>
  <approvaldate>4/06/2014</approvaldate>
  <actrnumber>ACTRN12614000594628</actrnumber>
  <trial_identification>
    <studytitle>The effect of vitamin D supplement in subjects with type 2 diabetes mellitus</studytitle>
    <scientifictitle> The effect of vitamin D supplement in glycemic control and lipid profile in type 2 diabetes mellitus (DM): an intervention study </scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type2 diabetes mellitus</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Each diabetic subject will take 4500 IU/day of  vitamin D3 oral drops for two months. During this period, patients will advise to record any compliance or possible side effects of the drug. After 2 months, all physical examination and laboratory measures that had done at first visit will be repeated.</interventions>
    <comparator>None</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>25(OH) vitamin D level will be evaluated by serum assay.</outcome>
      <timepoint> Two months after completing taking of 4500 IU/ day of vitamin D oral drops.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Fasting blood glucose will be evaluated by serum assay.</outcome>
      <timepoint>Two months after completing taking of 4500 IU/ day of vitamin D oral drops.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Lipid profile will be evaluated by serum assay. </outcome>
      <timepoint>Two months after completing taking of 4500 IU/ day of vitamin D oral drops.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>nil</outcome>
      <timepoint>nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Adult subjects with type 2 diabetes mellitus</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>We should exclude any subjects with hepatic, renal malignancy, bone disease, gall bladder disease, and gastrointestinal disease, history of anticonvulsants, calcium, or vitamin D intake for the last 3 months</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/03/2014</anticipatedstartdate>
    <actualstartdate>1/03/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Ain Shams University</primarysponsorname>
    <primarysponsoraddress>12 Khalifa El-Maamon St
Cairo, 
Egypt
PO Box 11566
</primarysponsoraddress>
    <primarysponsorcountry>Egypt</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary> Vitamin D supplement may help in glycemic control and lipid profile in subjects with diabetes mellitus (DM). Our subjects will take 4500 IU/ day of vitamin D tables for two months. Physical examination and  some laboratory measures will be formed before and after vitamin D supplement. The laboratory measures are fasting blood glucose, glycated hemoglobin, lipid profile. We will compare these measures to explore the effect of vitamin D in those with diabetes mellitus.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes>I think that there is no problem in recruiting the participants prior obtaining ethical approval because in  this trial vitamin D is safe and  approved for marketing. So, no harmful effect will be exist on our selected subjects till ethical approval. Beside this, our trail is open study not blinded and our selected cases will be informed before supplement with informed consent.  </publicnotes>
    <ethicscommitee>
      <ethicname>European Medicines Agency </ethicname>
      <ethicaddress>7 Westferry Circus, Canary Wharf, London E14 4HB</ethicaddress>
      <ethicapprovaldate />
      <hrec>2014-002258-38 </hrec>
      <ethicsubmitdate>1/04/2014</ethicsubmitdate>
      <ethiccountry>United Kingdom</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment>
    <filepath>http://www.anzctr.org.au/AnzctrAttachments/366105-2014-002258-38 3rd Country 20140526 Form.pdf</filepath>
  </attachment>
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Magda Mohamad</name>
      <address>Ain Shams University
12 Khalifa El-Maamon St
Cairo
Egypt
PO Box  11566</address>
      <phone>+201010938272805</phone>
      <fax />
      <email>magdaibrahim_bio@hotmail.com</email>
      <country>Egypt</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Magda Mohamad</name>
      <address>Ain Shams University
12 Khalifa El-Maamon St
Cairo
Egypt
PO Box  11566</address>
      <phone>+2010938272805</phone>
      <fax />
      <email>magdaibrahim_bio@hotmail.com</email>
      <country>Egypt</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Magda Mohamad</name>
      <address>Ain Shams University
12 Khalifa El-Maamon St
Cairo
Egypt
PO Box  11566</address>
      <phone>+2010938272805</phone>
      <fax />
      <email>magdaibrahim_bio@hotmail.com</email>
      <country>Egypt</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>